Allogene Therapeutics (ALLO)CFO sold ~$46K
Geoffrey M. Parker, CFO at Allogene Therapeutics, sold ~$46K of Allogene Therapeutics shares.
- ~$46K
- Approx. value · 37K sh @ $1.26
- 1.28M
- Holds after · shares reported
- Traded
- Oct 21, 2025
- Filed
- Oct 23, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 21, 2025 · this disclosureInsiderCFO sold ~$46K of ALLO shares in the open market
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Allogene Therapeutics
For Allogene Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALLO page.
Other recent filings by Geoffrey M. Parker, CHIEF FINANCIAL OFFICER
- SEC Form 4 at Allogene Therapeutics (ALLO)Feb 4, 2026
- SEC Form 4 at Perrigo (PRGO)Aug 20, 2025
- SEC Form 4 at Perrigo (PRGO)May 14, 2025
- SEC Form 4 at Allogene Therapeutics (ALLO)Feb 5, 2025
The full history of Geoffrey M. Parker, CHIEF FINANCIAL OFFICER is on the profile page.
How this filing works
Other disclosures at Allogene Therapeutics
- SEC Form 4Aug 25, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 4Apr 23, 2026
- SEC Form 4Apr 2, 2026
- SEC Form 4Mar 18, 2026
- SEC Form 4Mar 18, 2026
Everything OQRO holds on this company is on its ALLO page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
